Eli L Diamond1, David Russell1, Maria Kryza-Lacombe1, Kathryn H Bowles1, Allison J Applebaum1, Jeanne Dennis1, Lisa M DeAngelis1, Holly G Prigerson1. 1. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (E.L.D., M.K-L., L.M.D.); Center for Research on End of Life Care, Weill Cornell Medical College, New York, New York (E.L.D., H.G.P.); Center for Home Care Policy and Research, Visiting Nurse Service of New York, New York, New York (D.R., K.H.B.); Center for Integrative Science in Aging, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania (K.H.B.); Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York (A.J.A.); VNSNY Hospice Care, Visiting Nurse Service of New York, New York (J.D.).
Abstract
BACKGROUND: Primary malignant brain tumors (PMBTs) are devastating malignancies with poor prognosis. Optimizing psychosocial and supportive care is critical, especially in the later stages of disease. METHODS: This retrospective cohort study compared early versus late hospice enrollment of PMBT patients admitted to the home hospice program of a large urban, not-for-profit home health care agency between 2009 and 2013. RESULTS: Of 160 patients with PMBT followed to death in hospice care, 32 (22.5%) were enrolled within 7 days of death. When compared with patients referred to hospice more than 7 days before death, a greater proportion of those with late referral were bedbound at admission (97.2% vs 61.3%; OR=21.85; 95% CI, 3.42-919.20; P < .001), aphasic (61.1% vs 20.2%; OR = 6.13; 95% CI, 2.59-15.02; P < .001), unresponsive (38.9% vs 4%; OR = 14.76,;95% CI, 4.47-57.98; P < .001), or dyspneic (27.8% vs 9.7%; OR = 21.85; 95% CI, 3.42-10.12; P = .011). In multivariable analysis, male patients who were receiving Medicaid or charitable care and were without a health care proxy were more likely to enroll in hospice within 1 week of death. CONCLUSIONS: Late hospice referral in PMBT is common. PMBT patients enrolled late in hospice are severely neurologically debilitated at the time hospice is initiated and therefore may not derive optimal benefit from multidisciplinary hospice care. Men, patients with lower socioeconomic status, and those without a health care proxy may be at risk for late hospice care and may benefit from proactive discussion about end-of-life care in PMBT, but prospective studies are needed.
BACKGROUND:Primary malignant brain tumors (PMBTs) are devastating malignancies with poor prognosis. Optimizing psychosocial and supportive care is critical, especially in the later stages of disease. METHODS: This retrospective cohort study compared early versus late hospice enrollment of PMBT patients admitted to the home hospice program of a large urban, not-for-profit home health care agency between 2009 and 2013. RESULTS: Of 160 patients with PMBT followed to death in hospice care, 32 (22.5%) were enrolled within 7 days of death. When compared with patients referred to hospice more than 7 days before death, a greater proportion of those with late referral were bedbound at admission (97.2% vs 61.3%; OR=21.85; 95% CI, 3.42-919.20; P < .001), aphasic (61.1% vs 20.2%; OR = 6.13; 95% CI, 2.59-15.02; P < .001), unresponsive (38.9% vs 4%; OR = 14.76,;95% CI, 4.47-57.98; P < .001), or dyspneic (27.8% vs 9.7%; OR = 21.85; 95% CI, 3.42-10.12; P = .011). In multivariable analysis, male patients who were receiving Medicaid or charitable care and were without a health care proxy were more likely to enroll in hospice within 1 week of death. CONCLUSIONS: Late hospice referral in PMBT is common. PMBT patients enrolled late in hospice are severely neurologically debilitated at the time hospice is initiated and therefore may not derive optimal benefit from multidisciplinary hospice care. Men, patients with lower socioeconomic status, and those without a health care proxy may be at risk for late hospice care and may benefit from proactive discussion about end-of-life care in PMBT, but prospective studies are needed.
Authors: J A F Koekkoek; L Dirven; E M Sizoo; H R W Pasman; J J Heimans; T J Postma; L Deliens; R Grant; S McNamara; G Stockhammer; E Medicus; M J B Taphoorn; J C Reijneveld Journal: J Neurooncol Date: 2014-08-24 Impact factor: 4.130
Authors: Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag Journal: N Engl J Med Date: 2012-10-25 Impact factor: 91.245
Authors: José L Díaz; Pilar Barreto; José M Gallego; Javier Barbero; Ramón Bayés; Juan A Barcia Journal: Acta Neurochir (Wien) Date: 2009-02-18 Impact factor: 2.216
Authors: Akanksha Sharma; Briant Fruth; Celina Barrera; Hannah N Farfour; Maciej M Mrugala; Mark K Edwin; Jeff A Sloan; Alyx B Porter Journal: J Neurooncol Date: 2021-01-23 Impact factor: 4.130
Authors: Elie K Mehanna; Paul J Catalano; Daniel N Cagney; Daphne A Haas-Kogan; Brian M Alexander; James A Tulsky; Ayal A Aizer Journal: J Natl Cancer Inst Date: 2020-12-14 Impact factor: 13.506
Authors: Laura L Dover; Caleb R Dulaney; John B Fiveash; Courtney P Williams; Bradford E Jackson; Paula Warren; Gabrielle B Rocque Journal: JAMA Oncol Date: 2017-11-01 Impact factor: 31.777
Authors: A J Applebaum; K Buda; M Kryza-Lacombe; J J Buthorn; R Walker; K M Shaffer; T A D'Agostino; E L Diamond Journal: Psychooncology Date: 2017-12-19 Impact factor: 3.894
Authors: Kelly M Trevino; Holly G Prigerson; Megan Johnson Shen; Daniel J Tancredi; Guibo Xing; Michael Hoerger; Ronald M Epstein; Paul R Duberstein Journal: Cancer Date: 2019-05-30 Impact factor: 6.860
Authors: John H Holden; Hani Shamseddeen; Amy W Johnson; Benjamin Byriel; Kavitha Subramoney; Yao-Wen Cheng; Akira Saito; Marwan Ghabril; Naga Chalasani; Greg A Sachs; Eric S Orman Journal: J Palliat Med Date: 2020-02-24 Impact factor: 2.947